Pilot comparison of 18F-fluorocholine and 18F- fluorodeoxyglucose PET/CT with conventional imaging in prostate cancer

J. M. Beauregard, S. G. Williams, Timothy R DeGrado, P. Roselt, R. J. Hicks

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

Introduction: Conventional imaging (CI) is known to have limitations with respect to staging of patients with primary or relapsed prostate cancer. Positron emission tomography/computed tomography (PET/CT) with 18F-flurodeoxyglucose (FDG) is also often suboptimal because of low tracer avidity, but 18F-fluorocholine (FCH) appears to be a promising alternative molecular imaging probe. We report a prospective pilot study of PET/CT comparing both tracers for staging and restaging of patients with prostate cancer. Methods: Sixteen prostate cancer patients were evaluated (7 for staging and 9 for restaging). All patients also underwent CI, comprising at least an abdominopelvic CT and a bone scan. All imaging results and other relevant data were extracted from the imaging reports and medical charts. Results: Based on all imaging-detected disease sites, both FCH-PET/CT and FDG-PET/CT (79%) were more sensitive than CI (14%), with the highest number of sites of nodal and distant disease on FCH PET/CT. FCH-PET/CT alone would have provided sufficient clinical information to form an appropriate management plan in 88% of cases, as compared with 56% for CI. Conclusion: FCH-PET/CT has the potential to impact on the management of patients with prostate cancer significantly more often than CI.

Original languageEnglish (US)
Pages (from-to)325-332
Number of pages8
JournalJournal of Medical Imaging and Radiation Oncology
Volume54
Issue number4
DOIs
StatePublished - Aug 2010
Externally publishedYes

Fingerprint

Fluorodeoxyglucose F18
Prostatic Neoplasms
Molecular Probes
Molecular Imaging
Diagnostic Imaging
Positron Emission Tomography Computed Tomography
fluorocholine
Prospective Studies
Bone and Bones

Keywords

  • F-Fluorocholine
  • F-Fluorodeoxyglucose
  • cancer staging
  • positron emission tomography
  • prostate cancer

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Oncology

Cite this

Pilot comparison of 18F-fluorocholine and 18F- fluorodeoxyglucose PET/CT with conventional imaging in prostate cancer. / Beauregard, J. M.; Williams, S. G.; DeGrado, Timothy R; Roselt, P.; Hicks, R. J.

In: Journal of Medical Imaging and Radiation Oncology, Vol. 54, No. 4, 08.2010, p. 325-332.

Research output: Contribution to journalArticle

@article{f3ece2729c874b0cae899b366d6f9aeb,
title = "Pilot comparison of 18F-fluorocholine and 18F- fluorodeoxyglucose PET/CT with conventional imaging in prostate cancer",
abstract = "Introduction: Conventional imaging (CI) is known to have limitations with respect to staging of patients with primary or relapsed prostate cancer. Positron emission tomography/computed tomography (PET/CT) with 18F-flurodeoxyglucose (FDG) is also often suboptimal because of low tracer avidity, but 18F-fluorocholine (FCH) appears to be a promising alternative molecular imaging probe. We report a prospective pilot study of PET/CT comparing both tracers for staging and restaging of patients with prostate cancer. Methods: Sixteen prostate cancer patients were evaluated (7 for staging and 9 for restaging). All patients also underwent CI, comprising at least an abdominopelvic CT and a bone scan. All imaging results and other relevant data were extracted from the imaging reports and medical charts. Results: Based on all imaging-detected disease sites, both FCH-PET/CT and FDG-PET/CT (79{\%}) were more sensitive than CI (14{\%}), with the highest number of sites of nodal and distant disease on FCH PET/CT. FCH-PET/CT alone would have provided sufficient clinical information to form an appropriate management plan in 88{\%} of cases, as compared with 56{\%} for CI. Conclusion: FCH-PET/CT has the potential to impact on the management of patients with prostate cancer significantly more often than CI.",
keywords = "F-Fluorocholine, F-Fluorodeoxyglucose, cancer staging, positron emission tomography, prostate cancer",
author = "Beauregard, {J. M.} and Williams, {S. G.} and DeGrado, {Timothy R} and P. Roselt and Hicks, {R. J.}",
year = "2010",
month = "8",
doi = "10.1111/j.1754-9485.2010.02178.x",
language = "English (US)",
volume = "54",
pages = "325--332",
journal = "Journal of Medical Imaging and Radiation Oncology",
issn = "1754-9477",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Pilot comparison of 18F-fluorocholine and 18F- fluorodeoxyglucose PET/CT with conventional imaging in prostate cancer

AU - Beauregard, J. M.

AU - Williams, S. G.

AU - DeGrado, Timothy R

AU - Roselt, P.

AU - Hicks, R. J.

PY - 2010/8

Y1 - 2010/8

N2 - Introduction: Conventional imaging (CI) is known to have limitations with respect to staging of patients with primary or relapsed prostate cancer. Positron emission tomography/computed tomography (PET/CT) with 18F-flurodeoxyglucose (FDG) is also often suboptimal because of low tracer avidity, but 18F-fluorocholine (FCH) appears to be a promising alternative molecular imaging probe. We report a prospective pilot study of PET/CT comparing both tracers for staging and restaging of patients with prostate cancer. Methods: Sixteen prostate cancer patients were evaluated (7 for staging and 9 for restaging). All patients also underwent CI, comprising at least an abdominopelvic CT and a bone scan. All imaging results and other relevant data were extracted from the imaging reports and medical charts. Results: Based on all imaging-detected disease sites, both FCH-PET/CT and FDG-PET/CT (79%) were more sensitive than CI (14%), with the highest number of sites of nodal and distant disease on FCH PET/CT. FCH-PET/CT alone would have provided sufficient clinical information to form an appropriate management plan in 88% of cases, as compared with 56% for CI. Conclusion: FCH-PET/CT has the potential to impact on the management of patients with prostate cancer significantly more often than CI.

AB - Introduction: Conventional imaging (CI) is known to have limitations with respect to staging of patients with primary or relapsed prostate cancer. Positron emission tomography/computed tomography (PET/CT) with 18F-flurodeoxyglucose (FDG) is also often suboptimal because of low tracer avidity, but 18F-fluorocholine (FCH) appears to be a promising alternative molecular imaging probe. We report a prospective pilot study of PET/CT comparing both tracers for staging and restaging of patients with prostate cancer. Methods: Sixteen prostate cancer patients were evaluated (7 for staging and 9 for restaging). All patients also underwent CI, comprising at least an abdominopelvic CT and a bone scan. All imaging results and other relevant data were extracted from the imaging reports and medical charts. Results: Based on all imaging-detected disease sites, both FCH-PET/CT and FDG-PET/CT (79%) were more sensitive than CI (14%), with the highest number of sites of nodal and distant disease on FCH PET/CT. FCH-PET/CT alone would have provided sufficient clinical information to form an appropriate management plan in 88% of cases, as compared with 56% for CI. Conclusion: FCH-PET/CT has the potential to impact on the management of patients with prostate cancer significantly more often than CI.

KW - F-Fluorocholine

KW - F-Fluorodeoxyglucose

KW - cancer staging

KW - positron emission tomography

KW - prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=77955789181&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955789181&partnerID=8YFLogxK

U2 - 10.1111/j.1754-9485.2010.02178.x

DO - 10.1111/j.1754-9485.2010.02178.x

M3 - Article

C2 - 20718912

AN - SCOPUS:77955789181

VL - 54

SP - 325

EP - 332

JO - Journal of Medical Imaging and Radiation Oncology

JF - Journal of Medical Imaging and Radiation Oncology

SN - 1754-9477

IS - 4

ER -